CA2205175A1 - Vaccin polynucleotidique contre la tuberculose - Google Patents

Vaccin polynucleotidique contre la tuberculose

Info

Publication number
CA2205175A1
CA2205175A1 CA 2205175 CA2205175A CA2205175A1 CA 2205175 A1 CA2205175 A1 CA 2205175A1 CA 2205175 CA2205175 CA 2205175 CA 2205175 A CA2205175 A CA 2205175A CA 2205175 A1 CA2205175 A1 CA 2205175A1
Authority
CA
Canada
Prior art keywords
dna
mice
vaccinated mice
response
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2205175
Other languages
English (en)
Other versions
CA2205175C (fr
Inventor
Margaret A. Liu
Donna Montgomery
Jeffrey Ulmer
Jean Content
Kris Huygen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/338,992 external-priority patent/US5736524A/en
Application filed by Individual filed Critical Individual
Publication of CA2205175A1 publication Critical patent/CA2205175A1/fr
Application granted granted Critical
Publication of CA2205175C publication Critical patent/CA2205175C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2205175 1994-11-14 1995-11-13 Vaccin polynucleotidique contre la tuberculose Expired - Fee Related CA2205175C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/338,992 US5736524A (en) 1994-11-14 1994-11-14 Polynucleotide tuberculosis vaccine
US08/338,992 1994-11-14
PCT/US1995/014899 WO1996015241A2 (fr) 1994-11-14 1995-11-13 Vaccin polynucleotidique contre la tuberculose

Publications (2)

Publication Number Publication Date
CA2205175A1 true CA2205175A1 (fr) 1996-05-23
CA2205175C CA2205175C (fr) 2008-02-19

Family

ID=29405857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2205175 Expired - Fee Related CA2205175C (fr) 1994-11-14 1995-11-13 Vaccin polynucleotidique contre la tuberculose

Country Status (1)

Country Link
CA (1) CA2205175C (fr)

Also Published As

Publication number Publication date
CA2205175C (fr) 2008-02-19

Similar Documents

Publication Publication Date Title
WO1996015241A3 (fr) Vaccin polynucleotidique contre la tuberculose
Saxena et al. Pre-existing immunity against vaccine vectors–friend or foe?
Kamath et al. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis
Reed et al. Prospects for a better vaccine against tuberculosis
Morris et al. The immunogenicity of single and combination DNA vaccines against tuberculosis
Bastos et al. Recombinant mycobacterium bovis BCG
EP1523331B1 (fr) Vaccin therapeutique contre la tuberculose
ATE277181T1 (de) Tuberkulose-impfstoff
CA2132836A1 (fr) Immunisation par injection d'une unite de transcription genetique
Wedlock et al. Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone
Branger et al. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge
Bumann Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4+-T-cell responses
Blander et al. Vaccination with Legionella pneumophila membranes induces cell-mediated and protective immunity in a guinea pig model of Legionnaires' disease. Protective immunity independent of the major secretory protein of Legionella pneumophila.
Palomares-Resendiz et al. Immunogenic response of Brucella canis virB 10 and virB 11 mutants in a murine model
CA2205175A1 (fr) Vaccin polynucleotidique contre la tuberculose
Golshani et al. Comparison of the protective immunity elicited by a Brucella cocktail protein vaccine (rL7/L12+ rTOmp31+ rSOmp2b) in two different adjuvant formulations in BALB/c mice
Ohara et al. Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant Bacillus Calmette-Guerin over-producing three putative protective antigen candidates
Huygen DNA vaccines against mycobacterial diseases
Vordermeier et al. Development of cattle TB vaccines in the UK
CN102247595A (zh) 一种聚肌胞联合二甲基三十六烷基铵混合佐剂在制备结核亚单位疫苗中的应用
AU3980497A (en) A vector for polynucleotide vaccines
NEUPANEēē et al. Immunoprophylaxis against Mycobacterium leprae infection with subunit vaccines
Moradi et al. A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
Løvik et al. Induction of immunity against live Mycobacterium lepraemurium: a requirement for viable bacilli?
CN101428143A (zh) 携带结核基因的减毒细菌载体结核疫苗及制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed